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Objective: More than 50% of aortocoronary saphenous vein grafts are occluded 10
years after surgery. Intimal hyperplasia is an initial, critical step in the progression
toward occlusion. To date, no clinically relevant large animal models of aortocoro-
nary saphenous vein graft intimal hyperplasia have been fully characterized. Gene
therapy holds promise as a novel treatment for aortocoronary saphenous vein graft
intimal hyperplasia. The 2 objectives of this study are to characterize a canine model
of aortocoronary saphenous vein graft intimal hyperplasia and to demonstrate that
ex vivo gene delivery is possible in these grafts using adenoviral vectors.
Methods: Ten dogs underwent aortocoronary bypass grafting using saphenous
veins. Six dogs underwent serial arteriograms to monitor graft patency. On post-
operative day 90, the dogs were killed and their grafted and nongrafted saphenous
veins were studied histologically. Four dogs underwent the same procedure, but
their saphenous veins were treated with 1 1012 total viral particles of a replication-
deficient, recombinant adenovirus containing -galactosidase (n  2) or the -ad-
renergic receptor kinase carboxyl terminus (n  2). These animals were killed on
postoperative day 7 for determination of transgene expression.
Results: All grafts were demonstrated patent by arteriogram before the animals were
killed. The mean intimal area of the saphenous vein grafts was increased when
compared with that of the nongrafted saphenous veins (2.83 mm2 vs 0.09 mm2, P
 .0008). Adenoviral-treated saphenous vein grafts demonstrated positive transgene
expression either by X-gal staining (-galactosidase) or Northern analysis (-
adrenergic receptor kinase carboxyl terminus).
Conclusion: This study characterizes a clinically relevant canine model of aortocoro-
nary saphenous vein graft intimal hyperplasia. In addition, it demonstrates that adeno-
viral vectors can be delivered ex vivo to the saphenous vein graft vessel wall at
subphysiologic distension pressures. This model may be used in future studies to
manipulate molecular targets critical in aortocoronary saphenous vein graft intimal
hyperplasia.
Saphenous vein grafts (SVGs) are the most common conduit used forsurgical revascularization procedures, including coronary artery by-pass grafting. Unfortunately, these grafts are susceptible to the devel-opment of intimal hyperplasia (IH) and accelerated atherosclerosis,which result in 5- and 10-year failure rates of 20% and 50%, respec-tively.1,2 IH is a chronic structural lesion that develops after vein graft
implantation and leads to luminal stenosis and occlusion. It is generally defined as
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abnormal migration and proliferation of vascular smooth
muscle cells (VSMCs) with associated deposition of an
extracellular connective tissue matrix. SVG IH has been
demonstrated in experimental models of vessel injury, in-
flammation, and increased wall stress.3 Accordingly, mul-
tiple interventions have been proposed to limit endothelial
trauma and inflammation and several are now standard of
care (eg, the “no touch” SVG harvest technique and post-
operative aspirin therapy).4-6 Despite these treatments, long-
term SVG failure secondary to IH remains an important
cause necessitating redo coronary artery bypass grafting.
More recently, novel molecular approaches to inhibit IH
have been proposed and studied. Specifically, multiple mo-
lecular targets have been identified as critical regulators of
the VSMC proliferation and migration that result in IH and
graft stenosis.7-11 The possibility of delivering transgenes
selectively into the vessel wall to inhibit critical molecular
pathways holds considerable promise as a therapeutic tool.
The hope is that local production of the transgene product
will translate into reduced VSMC proliferation and, ulti-
mately, improved SVG durability.
Gene therapy has been used successfully to inhibit
VSMC proliferation and migration in multiple in vitro
studies. Gene therapy has also been shown to inhibit IH
in several in vivo studies of noncoronary vein grafts.
Most often, these studies have used naked DNA plasmids
or transgenes delivered in replication-deficient viral vec-
tors.7-11 Similar therapies may be useful in preventing
aortocoronary SVG IH, but no clinically relevant large
animal models of this pathologic process have been
quantitatively characterized. Such a model is appealing
because it allows an opportunity to study the efficacy of
gene therapy in a setting that may provide a bridge to
clinical trials.
The 2 objectives of this study are (1) to characterize a
canine model of aortocoronary SVG IH and (2) to demon-
strate efficient transgene expression in the SVG vessel wall
using an ex vivo treatment with adenoviral vectors.
Methods
SV Harvesting
Animals used in this study were mongrel dogs (weighing 27-32
kg). All procedures were performed in accordance with the regu-
lations adopted by the National Institutes of Health and approved
by the Animal Care and Use Committee of Duke University. After
placement of an intravenous line, each dog was sedated with
sodium pentothal (10 mg/kg). The dog was intubated, and anes-
thesia was maintained with inhaled isoflurane (1%-5%). The ani-
mal was anticoagulated with heparin (100 U/kg) to an activated
clotting time greater than 300. After sterile preparation, 7 to 10 cm
of SV was harvested from the left hind leg. The SV was flushed
and submerged in 3% albumin until anastomoses were performed.
The hind leg was closed in layers.
Treatment of Vein Grafts with Adenoviral-Mediated
Transgene
The adenoviral backbone for the vectors is a second-generation,
replication-deficient serotype-2 adenovirus with deletions of the
E1 and E4 genes.12 The deletions of these genes render the
adenovirus unable to replicate. The coding sequences for cytoplas-
mic -galactosidase (-gal) and the -adrenergic receptor kinase
carboxyl terminus (ARKct) were spliced into this adenoviral
backbone to generate the vectors Adeno--gal and Adeno-
ARKct.12 For animals treated with adenovirus (n  4), the distal
tip of the SV was ligated after routine inspection for defects, and
1  1012 total virus particles were thawed and suspended in 3 mL
of phosphate-buffered saline (PBS). This solution was delivered
intraluminally with a measured distension pressure of approxi-
mately 10 mm Hg. After a 20-minute incubation time, the distal
SV tip was reopened. The SV was flushed with heparinized saline
and resubmerged in 3% albumin until the proximal anastomosis
was performed.
Aortocoronary Reversed SVG Bypass
Under sterile conditions, a partial lower sternotomy was per-
formed, and a chest retractor was placed. A Satinsky clamp was
applied to partially occlude the ascending aorta, and an aortotomy
was created. An end-to-side, running anastomosis was performed
with 6-0 Prolene. An ACROBAT stabilizer (Guidant; Santa Clara,
Calif) was positioned over the distal left anterior descending
coronary artery. A coronary arteriotomy was created, and a stan-
dard end-to-side running anastomosis was performed with 7-0
Prolene. The proximal left anterior descending coronary artery was
ligated, rendering the anterior left ventricle SVG-dependent. An
ultrasonic vascular probe (Transonic Systems; Ithaca, NY) con-
firmed flow through the SVG. A mediastinal tube was inserted, the
sternum was reapproximated with interrupted sutures, and the
chest was closed in layers. Buprenorphine hydrochloride (0.5 mg
intramuscularly) was administered every 8 to 12 hours for 48 hours
after the surgery and then as needed. Dogs were maintained on
buffered aspirin (325 mg/day) throughout the protocol.
Arteriographic Confirmation of SVG Patency
At postoperative days (PODs) 30, 60, and 90, each dog underwent
arteriography and intravascular ultrasound (IVUS) of SVGs. Dogs
were sedated as before. Access to the femoral artery was obtained,
and a vascular sheath was inserted. A 6F coronary catheter was
directed into the aortic root under fluoroscopic guidance. Radio-
dense contrast dye was used to find, gain access to, and confirm
patency of the SVG.
IVUS Monitoring of Graft Wall Thickness
When possible, SVGs were imaged using a 6F IVUS probe to
monitor wall thickness. After access was gained to the distal SVG
by the use of a guidewire, the IVUS probe was manually retracted
to generate ultrasonic cross-sectional images of the SVG wall.
Histologic Preparation
After the POD 90 arteriogram, dogs were killed with a lethal dose
of intra-arterial pentobarbital sodium 390 mg/mL and phenytoin
sodium 50 mg/mL (Euthasol; Delmarva Laboratories, Midlothian,
Va). Each SVG and nongrafted SV from the right hind limb were
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harvested and placed into 10% formalin for 24 hours. SVG and
nongrafted SV segments were embedded in paraffin and cut in
cross-section for histologic staining and measurements. Cross-
sections (5 m) were taken every 0.5 cm and prepared with a
modified hematoxylin-eosin stain.
Measurement of IH
All SVG vessel sections were digitally photographed at 5 mag-
nification. A photomicrograph demonstrating maximal IH from
each third of each SVG was analyzed. For each SVG section
analyzed, the intimal area, medial area, maximal wall thickness,
and minimal wall thickness were determined using Image Tool
v.3.0 (The University of Texas Health Sciences Center, San An-
tonio, Tex). Mean values were calculated for each SVG. The
intima and media were delineated by the demarcation between the
radial orientation of the intimal smooth muscle cells and the more
circular orientation of the medial smooth muscle cells, as previ-
ously described.13 The outer limit of the media was defined by the
interface between the circular smooth muscle cells of the media
and the connective tissue of the adventitia. The ratio of the intimal
and medial areas (intima area/media area) was calculated. Similar
measurements and calculations were performed for 2 representa-
tive sections from each nongrafted SV.
Confirmation of Transgene Expression in SVGs
Dogs treated with adenoviruses (n  4) were killed on POD 7 as
before, and the SVG was harvested. For dogs treated with Adeno-
-gal (n  2), specimens were mounted on a freezing microtome,
and 10-m sections were transferred to pretreated glass slides.
Sections were fixed in 10% formalin for 2 minutes at room
temperature and washed in PBS; -gal staining was performed as
previously described.9 After staining (30-60 minutes at 37°C), the
sections were rinsed in PBS solution and counterstained with
eosin. For dogs treated with Adeno-ARKct (n  2), the vessels
were excised, total RNA was isolated, and Northern analysis was
performed by standard methods previously described.9
Statistical Analysis
Comparisons between SVGs and nongrafted SVs were made using
unpaired, 2-tailed Student t tests. All data are represented as mean
 SEM.
Results
Assessment of SVG Patency
SVGs from all dogs in this study (n  10) were confirmed
patent immediately after completion of the distal anastomo-
sis with an ultrasonic vascular flow probe. Flow values for
each animal were 18 mL/min or greater. Serial arteriograms
at PODs 30, 60, and 90 revealed progressive filling defects
consistent with graft wall thickening (Figure 1). At POD 30,
most SVGs (4/6) were without filling defects. By POD 90,
all SVGs displayed filling defects. Attempted serial IVUS
confirmed the progression of SVG wall thickening, but this
was obtained consistently only on POD 30 (5/6 dogs). By
POD 90, the IVUS catheter could not be introduced into any
of the diseased SVGs, and therefore IVUS was not per-
formed.
Histologic Analysis
The mean intimal area of SVGs was increased compared
with nongrafted SVs (2.83  0.57 mm2 vs 0.09  0.01
mm2, P  .0008). Differences in mean medial area (2.21 
0.19 mm2 vs 1.10  0.19 mm2, P  .01), mean intima and
media ratio (1.22 vs 0.09, P  .0001), mean maximal wall
thickness (1.94  0.18 mm vs 0.39  0.06 mm, P  .005),
and mean minimal wall thickness (0.71  0.08 mm vs 0.23
 0.03 mm, P  .0003) also were significant. Representa-
tive photomicrographs from a single dog are displayed in
Figure 2.
Figure 1. A, POD 30 arteriogram from a representative dog reveals a patent SVG devoid of filling defects. B, The
same SVG is imaged on POD 90; multiple filling defects are apparent, suggestive of SVG disease and IH. SVG,
Saphenous vein graft.
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Assessment of Gene Transfection
A subset of dogs (n  4) had their SVGs treated with a
replication-deficient, recombinant adenovirus. These ani-
mals were put to death on POD 7. Adeno--gal–treated
SVGs (n  2) demonstrated nonuniform (patchy) transgene
expres-sion by X-gal staining relative to untreated SVGs
(Figure 3, A and B). Gene expression was noted in all layers
of the SVG wall. Adeno-ARKct–treated SVGs demon-
strated transgene expression by Northern analysis relative to
nontreated SVGs (Figure 3, C).
Figure 3. X-gal–stained sections of an Adeno--gal–treated SVG (A) versus nontreated SVG (B). Northern blot
analysis using a radiolabeled ARKct probe (C). (1) POD 7 Adeno-ARKct–treated SVG. (2) POD 7 nontreated SVG.
(3) Untreated myocardium (negative control). (4) Direct myocardial injection of Adeno-ARKct (positive control).
ARKct, -Adrenergic receptor kinase carboxyl terminus.
Figure 2. Hematoxylin-eosin–stained slides of (A) nongrafted SV and (B) SVG from a representative dog put to
death on POD 90. Borders between the intima, media, and adventitia (arrows). Scale  1 mm.
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Discussion
Aortocoronary SVG IH is a critical, initial event leading to
subsequent vessel occlusion. Current treatment modalities
are limited in their ability to effectively prevent this process.
Novel genetic treatments directed at molecular targets to
temper the development of vein graft IH are appealing and
have generated considerable interest. However, a clinically
relevant experimental model of aortocoronary SVG IH has
not been fully characterized.
Previous studies have described the progression of SVG
IH in canine aortocoronary SVGs.14-16 None of the previous
investigations quantified the amount of IH that developed in
the SVGs; each simply described the pathologic changes
that occurred. In addition, the number of specimens ana-
lyzed at any single time point is very small. Silver and
colleagues16 followed only 3 dogs (and only 1 at each of the
3 time points) to generate their conclusions. Brody and
colleagues15 included 29 dogs in their study, but only 9
were killed for histologic analysis. Furthermore, only 2 of
these 9 dogs were examined at POD 90. Finally, clinically
relevant techniques were not used. For example, all of these
articles describe distending the SV to 180 mm Hg before
implantation. The mechanical trauma and resultant de-
creased graft patency rates resulting from high-pressure
distension are well described, and, accordingly, this practice
is not clinically advisable. In contrast, the current article
offers a clinically relevant model that is described by re-
producible, statistically supported measurements.
For a model of vein graft IH to be pertinent, blood flow
and graft patency must be maintained throughout the pro-
tocol. In this model, flow and patency were confirmed at
regular intervals. Flow probe data confirmed SVG patency
immediately after completion of the anastomoses. Serial
arteriography on PODs 30, 60, and 90 confirmed SVG
patency to the conclusion of the protocol. Arteriography and
IVUS also provided qualitative data regarding disease for-
mation in each SVG. These surveillance techniques avoided
killing animals at earlier time points. Serial arteriograms
noted the steady progression of diffuse SVG disease in each
animal. By POD 90, filling defects were noted in all SVGs.
IVUS confirmed that the filling defects noted on arteriogram
were caused by overall wall thickening rather than mural
thrombus.
Histologic analysis confirmed the earlier qualitative re-
sults by quantifying the extent of SVG disease. The mean
intimal area was more than 30 times greater in the SVGs
when compared with nongrafted SVs. The average medial
thickening, intimal and medial ratio, maximal wall thick-
ness, and minimal wall thickness were similarly increased in
the SVGs.
The second objective of this study was to demonstrate
that ex vivo transfer of a replication-deficient, recombinant
adenovirus vector was possible in SVGs using a delivery
technique that was unlikely to damage the vessel endothe-
lium. Transgene delivery to SVGs is valuable because mul-
tiple molecular pathways have been identified as important
contributors to IH formation and may represent targets for
IH treatment. Inhibition of intracellular superoxides, extra-
cellular matrix metalloproteinases, and nuclear apoptotic
proteins impede VSMC proliferation and vascular IH.8,17,18
Our laboratory demonstrated IH reduction in a rabbit pe-
ripheral vein graft model through inhibition of heterotri-
meric G-protein–mediated mitogenic signaling.13,19 Specif-
ically, we used a peptide inhibitor of G-protein beta-gamma
subunits (G)—the ARKct. ARKct is a peptide derived
from the ARK that binds to G before that subunit’s
activation.20 G seems to be a key molecule in VSMC
proliferation.21
A previous study showed that ex vivo adenoviral-medi-
ated transgene delivery was possible in canine aortocoro-
nary SVGs.22 To achieve transgene expression, the investi-
gators distended the SV at high pressures (75 mm Hg) for
1 hour. Prior studies described an inverse relationship be-
tween preimplantation SVG manipulation and patency.4
Elevated distension pressures have been demonstrated to
specifically injure the fragile SV endothelium that is a
critical regulator for vessel hemostasis and VSMC prolifer-
ation.23-26 So, although this technique achieved transgene
expression, prolonged high-pressure distension is not a
common clinical practice. This delivery technique itself
may disrupt the vessel endothelium and lead to IH.
We demonstrate a method of gene delivery using clini-
cally relevant conditions. Both -gal and ARKct were
expressed in SVGs on POD 7 after distending the vessel
lumen to subphysiologic pressures for 20 minutes. This
finding is appealing because it offers a convenient, nontrau-
matic opportunity for focused SVG treatment. Ehsan and
colleagues27 used nondistending, high pressures (300 mm
Hg) after placing the SV in an inelastic sheath to transfer
DNA oligonucleotides. This technique focuses on deliver-
ing small DNA molecules rather than larger genes. None-
theless, the principle of protecting the vessel endothelium
by minimizing distension pressures remains important in
any proposed treatment to limit SVG IH and enhance long-
term patency. The gene transfer method described in this
article warrants comparison with the high-pressure, nondis-
tending technique.
This canine model of aortocoronary SVG IH is not
without limitations. Although we attempted to maximize
clinical relevance throughout this study, the time course to
canine SVG IH is noticeably less than in humans. In pa-
tients, SVG IH typically takes years to become clinically
significant, rather than weeks or months. One explanation of
this abbreviated time course may be that the typical resting
canine mean arterial blood pressure (80-120 mm Hg) is
higher compared with that of humans.28 This increased
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blood pressure may contribute to increased wall stress (and
accelerated SVG IH) in the canine SV.
Conclusion
This study characterizes a large animal model of aortocoro-
nary SVG IH that may serve as a testing ground for a variety
of promising molecular therapies. In addition, it demon-
strates that efficient transgene expression in the SVG vessel
wall is possible following a clinically relevant, ex vivo
treatment with replication-deficient, recombinant adenovi-
rus vectors.
We thank the Genzyme Corporation for production of Adeno-
ARKct. We also thank George Quick, Ronald Johnson, Elaine
Parker, and Mike Lowe for their valuable technical support during
all procedures in this study.
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Discussion
Dr Frank W. Sellke (Boston, Mass). That was a very nice
presentation. Vein graft disease after aortocoronary surgery is a
long-term issue or problem. Do you think that you could transfect
the veins with a gene that may have more of a long-term conse-
quences as opposed to ARK (which may have short-term ef-
fects)? If so, what would those genes be?
Dr Petrofski. Well, more so than just a specific gene would be
the virus on which the transgene is carried. We are using a
first-generation viral vector, which in our laboratory produces
transgene expression for approximately 14 days. Other virus car-
riers may produce longer transgene expression. Certainly retrovi-
ruses incorporate into the host genome and theoretically result in
indefinite transgene expression. This of course leads you to the
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potential problem that transgene expression would remain forever,
and any long-term effects could become deleterious.
Dr Sellke. I was curious that you used ARK, which is a
protein involved with signal transduction in the adrenergic path-
way. How does this inhibit IH?
Dr Petrofski. That is a good question. What we are using is
actually the carboxyl terminus of ARK, which is the last 194
amino acids. The proposed mechanism that we have seen in
previous in vitro work in isolated VSMCs and in some rabbit
models of jugular vein interposition grafts is that the ARKct
blocks the beta gamma subunit of G-protein–coupled receptors. In
work by Drs Koch and Lefkowitz, G-protein–coupled receptors
have been shown to stimulate the Ras/mitogen-activated protein
(MAP) kinase pathway. That Ras/MAP kinase pathway is critical
in VSMC proliferation. So the last 194 amino acids, the carboxyl
terminus, competitively inhibits that beta gamma subunit, and that
is the proposed mechanism that we are working with at this point.
Dr Sellke. How about giving a MAP kinase inhibitor or some
gene encoding a protein that would effectively do that? Is that
another potential treatment?
Dr Petrofski. This area of IH in diseased coronary arteries and
vein grafts is under active investigation by laboratories throughout
the country, and although I am not familiar with every gene out
there, clearly there are multiple genes just at our institution that we
are going to try in this model. In fact, the way that the ARKct
works is by inhibiting the stimulus of the MAP kinase pathway.
Dr Aftab R. Kherani (New York, NY). I enjoyed your talk, and
in line with your first future consideration, do you have any early
long-term data comparable to that obtained while developing your
model at PODs 30, 60, or 90 in regard to ARKct?
Dr Petrofski. Obviously the point of doing all this is not just
an academic exercise but to actually test genes in this model, and
we started by treating the grafts with Adeno-ARKct. Our initial
data are quite encouraging with 6 dogs in each branch of the
testing (6 controls and 6 ARKct-treated dogs). The intimal area
was decreased approximately 50% in the ARKct-treated grafts,
which is consistent with previous studies from our laboratory in
the rabbit model and also in VSMC proliferation in isolated in
vitro studies.
Dr Paul A. Kurlansky (Miami Beach, Fla). I enjoyed your
presentation. Just a quick thought regarding an issue that Dr Sellke
raised. The stimulus for hyperplasia, although it may occur early,
may persist throughout the life of the graft. However, to the extent
that the cells are viable, the vector, once introduced, does not have
to remain. The gene, once implanted, may become active, and
there are various genes that can be turned on and off with various
signals. That is perhaps a rich area to explore in this particular
model so that you can get a long-term effect that could be mod-
ulated with drug therapy over time.
Dr Petrofski. I appreciate the comments. IH is a very complex
pathology that has multiple stimuli, and we are only beginning to
understand all of them. We hope, though, that with continued
investigation and potentially newer viral backbones that we can
keep the gene in longer, which may be a long-term benefit in this
disease.
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